Previous 10 | Next 10 |
Alvotech ( NASDAQ: ALVO ) and its partner, Germany-based generic drugmaker STADA Arzneimittel AG, on Thursday announced the launch of Hukyndra, their biosimilar to AbbVie's ( ABBV ) blockbuster Humira drug, in Switzerland. Iceland-based ALVO develops and makes Hukyndra...
Hukyndra ® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumab Exclusive partnership between Alvotech and STADA in Europe includes Hukyndra ® and six biosimilar candidates REYKJAVIK, Iceland and BAD VIL...
The U.S. Food and Drug Administration issued a letter to Alvotech's ( NASDAQ: ALVO ) application seeking approval of AVT02, a biosimilar of AbbVie's ( ABBV ) drug Humira, citing certain deficiencies in the company's manufacturing facility in Reykjavik, Iceland. ...
REYKJAVIK, Iceland, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Alvotech received communication from the U.S. Food and Drug Administr...
Alvotech (ALVO) Q2 2022 Earnings Conference Call September 1, 2022 08:00 ET Company Participants Benedict Stephan - Investor Relations Robert Wessman - Executive Chairman & Founder Mark Levick - Chief Executive Officer Anil Okay - Chief Commercial Officer...
Alvotech press release ( NASDAQ: ALVO ): 1H GAAP EPS of -$1.02. Revenue of $40.1M (+1905.0% Y/Y). Cash and cash equivalents is of $128.4M For further details see: Alvotech GAAP EPS of -$1.02, revenue of $40.1M
Secured funding of approximately $185 million in gross proceeds through the merger with OACB (the “Business Combination”) and private placement investment in public equity (PIPE) financing Debuted as publicly traded company on Nasdaq Stock Exchange in U.S. and ...
Alvotech releases ESG indicators covering both 2020 and 2021 Carbon neutrality for scope 1 and 2 emissions achieved in 2020 and 2021 ESG portal is now available on the Company’s website at www.alvotech.com/corporate-sustainability Alvot...
Alvotech ( NASDAQ: ALVO ) said it began a confirmatory patient study for AVT03, a biosimilar of Amgen's ( NASDAQ: AMGN ) bone disorder drugs Prolia and Xgeva. The Iceland-based company said the aim of the trial is to show similarity of AVT03 to Pro...
Alvotech has now entered four biosimilar candidates into confirmatory patient studies Combined sales of Prolia ® and Xgeva ® (denosumab) which are used to treat bone diseases were nearly $5.3 billion in 2021 REYKJAVIK, Iceland, Aug. 25, 2022 (GLOBE NEWS...
News, Short Squeeze, Breakout and More Instantly...
Alvotech Company Name:
ALVO Stock Symbol:
NASDAQ Market:
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration in...
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi ® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritis Alvotech is the first company to publicly announce positiv...
U.S. stocks were mixed, with the Nasdaq Composite falling over 100 points on Friday. Shares of Fifth Third Bancorp (NASDAQ:FITB) rose during Friday...